Comparison 3.

Reslizumab (IV) versus placebo

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Rate of exacerbations requiring systemic corticosteroids	2	953	Rate Ratio (Fixed, 95% CI)	0.43 [0.33, 0.55]
1.1 Eosinophilic	2	953	Rate Ratio (Fixed, 95% CI)	0.43 [0.33, 0.55]
2 Rate of exacerbations requiring emergency department treatment or admission	2	953	Rate Ratio (Fixed, 95% CI)	0.67 [0.39, 1.17]
2.1 Eosinophilic	2	953	Rate Ratio (Fixed, 95% CI)	0.67 [0.39, 1.17]
3 Health‐related quality of life (AQLQ)	3	1164	Mean Difference (Fixed, 95% CI)	0.28 [0.17, 0.39]
3.1 Eosinophilic	3	1164	Mean Difference (Fixed, 95% CI)	0.28 [0.17, 0.39]
4 Health‐related quality of life (ACQ)	4	1652	Mean Difference (Fixed, 95% CI)	‐0.25 [‐0.33, ‐0.17]
4.1 Eosinophilic	4	1260	Mean Difference (Fixed, 95% CI)	‐0.27 [‐0.36, ‐0.19]
4.2 Non‐eosinophilic	1	392	Mean Difference (Fixed, 95% CI)	‐0.12 [‐0.33, 0.09]
5 Pre‐bronchodilator FEV1 (litres)	4	1652	Mean Difference (Fixed, 95% CI)	0.11 [0.07, 0.15]
5.1 Eosinophilic	4	1260	Mean Difference (Fixed, 95% CI)	0.12 [0.08, 0.16]
5.2 Non‐eosinophilic	1	392	Mean Difference (Fixed, 95% CI)	0.03 [‐0.07, 0.14]
6 Serious adverse events	4	1656	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.56, 1.12]
6.1 Eosinophilic	3	1160	Risk Ratio (M‐H, Random, 95% CI)	0.79 [0.51, 1.22]
6.2 Eosinophil status unknown	1	496	Risk Ratio (M‐H, Random, 95% CI)	0.98 [0.34, 2.88]
7 Adverse events leading to discontinuation	4	1659	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.43, 1.02]
7.1 Eosinophilic	3	1163	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.37, 1.20]
7.2 Eosinophil status unknown	1	496	Risk Ratio (M‐H, Random, 95% CI)	0.66 [0.35, 1.23]
8 Serum eosinophil level (cells/microlitre)	4	1656	Mean Difference (Fixed, 95% CI)	‐476.83 [‐499.32, ‐454.34]
8.1 Eosinophilic	4	1656	Mean Difference (Fixed, 95% CI)	‐476.83 [‐499.32, ‐454.34]